Shanghai Xuerong Bio-Technology Co Ltd

Xuerong Bio-technology released its 2026 interim report, with net profit attributable to the parent company of 17.8549 million yuan. The company's total operating revenue was 1.156 billion yuan, and net cash inflow from operating activities was 221 million yuan. The latest asset-liability ratio was 56.55 percent, up 2.06 percentage points from the previous quarter. Gross margin was 17.25 percent, down 16.38 percentage points from the previous quarter. Return on equity was 1.09 percent, and diluted earnings per share was 0.03 yuan. The company had 29,300 shareholders, and the top ten shareholders held 183 million shares, accounting for 28.54 percent of total share capital.